Loading…
Based on limited metadata, the FDA issued a Warning Letter to The Compounding Pharmacy on June 5, 2020, regarding drug compounding operations. While the specific violations cannot be detailed without access to the full letter text, the warning indicates regulatory concerns with the company's drug manufacturing or compounding practices. The letter falls under FDA's drug product oversight authority, though the specific issuing office is not identified in the available metadata.